112 related articles for article (PubMed ID: 25367937)
1. Small molecules inhibit the RAS-like small GTPases RALA and RALB.
Cancer Discov; 2014 Nov; 4(11):1251. PubMed ID: 25367937
[TBL] [Abstract][Full Text] [Related]
2. Discovery and characterization of small molecules that target the GTPase Ral.
Yan C; Liu D; Li L; Wempe MF; Guin S; Khanna M; Meier J; Hoffman B; Owens C; Wysoczynski CL; Nitz MD; Knabe WE; Ahmed M; Brautigan DL; Paschal BM; Schwartz MA; Jones DN; Ross D; Meroueh SO; Theodorescu D
Nature; 2014 Nov; 515(7527):443-7. PubMed ID: 25219851
[TBL] [Abstract][Full Text] [Related]
3. Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis.
Peschard P; McCarthy A; Leblanc-Dominguez V; Yeo M; Guichard S; Stamp G; Marshall CJ
Curr Biol; 2012 Nov; 22(21):2063-8. PubMed ID: 23063435
[TBL] [Abstract][Full Text] [Related]
4. RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer.
Yan C; Theodorescu D
Pharmacol Rev; 2018 Jan; 70(1):1-11. PubMed ID: 29196555
[TBL] [Abstract][Full Text] [Related]
5. Expression profiling of Ral-depleted bladder cancer cells identifies RREB-1 as a novel transcriptional Ral effector.
Oxford G; Smith SC; Hampton G; Theodorescu D
Oncogene; 2007 Nov; 26(50):7143-52. PubMed ID: 17496927
[TBL] [Abstract][Full Text] [Related]
6. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
[TBL] [Abstract][Full Text] [Related]
7. Drugging the Ral GTPase.
Yan C; Jones DN; Theodorescu D
Small GTPases; 2015; 6(3):157-9. PubMed ID: 26280620
[TBL] [Abstract][Full Text] [Related]
8. Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation.
Kidd AR; Snider JL; Martin TD; Graboski SF; Der CJ; Cox AD
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):205-12. PubMed ID: 20619549
[TBL] [Abstract][Full Text] [Related]
9. The RalGEF/Ral pathway: evaluating an intervention opportunity for Ras cancers.
Cooper JM; Bodemann BO; White MA
Enzymes; 2013; 34 Pt. B():137-56. PubMed ID: 25034103
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of novel Ral inhibitors: An in vitro and in vivo study.
Yan C; Theodorescu D; Miller B; Kumar A; Kumar V; Ross D; Wempe MF
Bioorg Med Chem Lett; 2016 Dec; 26(23):5815-5818. PubMed ID: 27825764
[TBL] [Abstract][Full Text] [Related]
11. Divergent roles of CAAX motif-signaled posttranslational modifications in the regulation and subcellular localization of Ral GTPases.
Gentry LR; Nishimura A; Cox AD; Martin TD; Tsygankov D; Nishida M; Elston TC; Der CJ
J Biol Chem; 2015 Sep; 290(37):22851-61. PubMed ID: 26216878
[TBL] [Abstract][Full Text] [Related]
12. Expression of ral GTPases, their effectors, and activators in human bladder cancer.
Smith SC; Oxford G; Baras AS; Owens C; Havaleshko D; Brautigan DL; Safo MK; Theodorescu D
Clin Cancer Res; 2007 Jul; 13(13):3803-13. PubMed ID: 17606711
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of RalB is important for bladder cancer cell growth and metastasis.
Wang H; Owens C; Chandra N; Conaway MR; Brautigan DL; Theodorescu D
Cancer Res; 2010 Nov; 70(21):8760-9. PubMed ID: 20940393
[TBL] [Abstract][Full Text] [Related]
14. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.
Lim KH; O'Hayer K; Adam SJ; Kendall SD; Campbell PM; Der CJ; Counter CM
Curr Biol; 2006 Dec; 16(24):2385-94. PubMed ID: 17174914
[TBL] [Abstract][Full Text] [Related]
15. RalA and RalB: antagonistic relatives in cancer cell migration.
Oxford G; Owens CR; Titus BJ; Foreman TL; Herlevsen MC; Smith SC; Theodorescu D
Cancer Res; 2005 Aug; 65(16):7111-20. PubMed ID: 16103060
[TBL] [Abstract][Full Text] [Related]
16. Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth.
Falsetti SC; Wang DA; Peng H; Carrico D; Cox AD; Der CJ; Hamilton AD; Sebti SM
Mol Cell Biol; 2007 Nov; 27(22):8003-14. PubMed ID: 17875936
[TBL] [Abstract][Full Text] [Related]
17. Differential involvement of RalA and RalB in colorectal cancer.
Martin TD; Der CJ
Small GTPases; 2012; 3(2):126-30. PubMed ID: 22790202
[TBL] [Abstract][Full Text] [Related]
18. Ral GTPases: crucial mediators of exocytosis and tumourigenesis.
Shirakawa R; Horiuchi H
J Biochem; 2015 May; 157(5):285-99. PubMed ID: 25796063
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.
Smith SC; Baras AS; Owens CR; Dancik G; Theodorescu D
Cancer Res; 2012 Jul; 72(14):3480-91. PubMed ID: 22586063
[TBL] [Abstract][Full Text] [Related]
20. Calmodulin binds RalA and RalB and is required for the thrombin-induced activation of Ral in human platelets.
Clough RR; Sidhu RS; Bhullar RP
J Biol Chem; 2002 Aug; 277(32):28972-80. PubMed ID: 12034722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
